A Phase II, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of tgAAC09, an HIV Vaccine Containing Clade C Gag-PR-ΔRT DNA in an Adeno-Associated Virus (AAV) Capsid, Administered Twice, at Three Dosage Levels and Two Dosing Intervals.

Trial Profile

A Phase II, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of tgAAC09, an HIV Vaccine Containing Clade C Gag-PR-ΔRT DNA in an Adeno-Associated Virus (AAV) Capsid, Administered Twice, at Three Dosage Levels and Two Dosing Intervals.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2012

At a glance

  • Drugs TgAAC 09 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 16 May 2009 Targeted Genetics Corporation added as trial sponsor, additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 28 Apr 2009 Actual end date (1 Dec 2007) added as reported by Clinicaltrials.gov record.
    • 28 Apr 2009 Actual initiation date (1 Oct 2005) added as reported by Clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top